ArticleEuropean journal of clinical pharmacology2010

Rofecoxib, but not celecoxib, increases the risk of thromboembolic cardiovascular events in young adults-a nationwide registry-based study.

Bjorn Gudbjornsson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.